Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study

To assess the relationship between responses within 1 year and health-related quality of life (HRQoL) outcomes by exploring profiles of patients with CML-CP who were treated with front-line imatinib or nilotinib.

Source: BMC Cancer - August 3, 2018 Category: Cancer & Oncology Authors: Lu Yu, Haibo Wang, Darko Milijkovic, Xiaojun Huang and Qian Jiang Tags: Research article Source Type: research